A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.
Medpage Today on MSN19h
No Clear Winner in SGLT2 Showdown for Cardiovascular Disease"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...
It says Farxiga will reach peak sales of $9 billion in 2028, with Jardiance forecast to reach $4.6 billion, assuming a launch for HFrEF this year. The bulk of those sales will come from HFpEF ...
With the passage of the Inflation Reduction Act (IRA) we saw millions of insulin dependent Medicare beneficiaries receive ...
Results from EMPA-KIDNEY are due in 2022. Jardiance is the market leader in the SGLT2 inhibitor class, ahead of AstraZeneca’s Farxiga (dapagliflozin) and Johnson & Johnson’s Invokana (canagl ...
FOX 9 Minneapolis-St. Paul on MSN5d
Ozempic, cancer treatments among 15 drugs to be negotiated by Medicare for lower pricesTradjenta -- A prescription medicine that is used to treat type 2 diabetes. Otezla – A prescription pill that treats plaque ...
As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...
Those drugs are Eliquis, Xarelto, Januvia Jardiance, Stelara, Imbruvica, Farxiga, Entresto, Enbrel, NovoLog and Fiasp insulins. Senator Klobuchar said Medicare beneficiaries will save between 38% ...
The Biden Administration enacted a slew of prescription drug cost reductions for seniors and citizens on Medicaid. The ...
The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...
Hays and her husband who have a Medicare Part D drug plan. As a result, she expects to shell out a lot less at the pharmacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback